What is a recommended topical steroid for plaque psoriasis?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: July 24, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Recommended Topical Steroids for Plaque Psoriasis

For plaque psoriasis, class 1 (ultrahigh-potency) topical corticosteroids are recommended for thick, chronic plaques, while class 2-5 (high to moderate potency) corticosteroids are recommended as initial therapy for most other presentations. 1

Selection Based on Plaque Characteristics

Plaque Thickness and Location

  • Thick, chronic plaques: Class 1 (ultrahigh-potency) corticosteroids such as clobetasol propionate or halobetasol propionate 1
  • Moderate plaques: Class 2-5 (high to moderate potency) corticosteroids 1
  • Face and intertriginous areas: Lower potency (class 6-7) corticosteroids to minimize adverse effects 1
  • Scalp psoriasis: Any class (1-7) of topical corticosteroids can be used 1

Efficacy Rates

  • Ultrahigh-potency (class 1) corticosteroids show efficacy rates of 58-92% in clinical trials 1
  • In one study, halobetasol propionate ointment (class 1) improved PGA scores by 92% compared to 39% with vehicle after 2 weeks 1
  • Another study showed clobetasol foam (class 1) achieved PSGA scores of 0-1 in 68% of patients after 2 weeks 1

Duration of Treatment

  • Initial treatment: 2-4 weeks 1
  • Extended use: Treatment beyond 12 weeks should only be done under careful physician supervision 1
  • Tapering strategy: Gradually reduce frequency of application after clinical improvement to prevent rebound 1

Vehicle Selection

The choice of vehicle significantly affects medication penetration and efficacy:

  • Ointments: Most effective for thick plaques, but greasy
  • Creams: Less greasy, better for daytime use
  • Solutions, foams, sprays: Ideal for scalp and hair-bearing areas
  • Occlusion: Can dramatically increase potency (e.g., flurandrenolide tape functions as a class 1 steroid despite being class 5 in cream form) 1

Combination Approaches

To enhance efficacy and reduce steroid-related adverse effects:

  • Vitamin D analogues + corticosteroids: More effective than either agent alone 1
    • Can be used as separate products or as combination products
    • Apply vitamin D in morning and corticosteroid in evening
    • Or use corticosteroids on weekends and vitamin D on weekdays
  • Coal tar + corticosteroids: Can be effective for maintenance therapy after initial clearance 2

Common Pitfalls and Caveats

  1. Adverse effects: Prolonged use of high-potency steroids can cause skin atrophy, striae, folliculitis, telangiectasia, and purpura 1
  2. High-risk areas: Face, intertriginous areas, and forearms are at greatest risk for adverse effects 1
  3. Rebound phenomenon: Abrupt discontinuation can lead to disease recurrence worse than before treatment 1
  4. Tachyphylaxis: Decreasing effectiveness with continued use
  5. Incompatible combinations: Avoid using calcipotriene with salicylic acid as the acidic pH inactivates calcipotriene 1

Practical Application Guidelines

  • Use the fingertip unit method to ensure appropriate quantity application 1
  • For maintenance therapy after initial clearance, consider:
    1. Weekend-only steroid use
    2. Combination with steroid-sparing agents like vitamin D analogues
    3. Switching to lower potency steroids for long-term management

Monitoring

  • Regular assessment for signs of skin atrophy and other local adverse effects
  • Systemic absorption is generally minimal with short-term use, with studies showing no clinically significant HPA axis suppression even in extensive disease 3

For patients with inadequate response to topical steroids alone, combination therapy with vitamin D analogues or transitioning to systemic therapies should be considered based on disease severity and impact on quality of life.

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

Topical corticosteroids in plaque psoriasis: a systematic review of risk of adrenal axis suppression and skin atrophy.

Journal of the European Academy of Dermatology and Venereology : JEADV, 2012

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.